A
Anviron develops small molecule inhibitors targeting proteins involved in unconstrained proliferation signaling and metastasis for late-stage cancers. Their lead candidate, ANV221, demonstrates efficacy in reducing tumor size and suppressing metastases in models of pancreatic ductal adenocarcinoma. This compound also halts tumor growth in triple-negative and HER2+ breast cancer models, showing potential for reversing drug resistance.
Updated 20 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Anviron develops small molecule inhibitors targeting proteins involved in unconstrained proliferation signaling and metastasis for late-stage cancers. Their lead candidate, ANV221, demonstrates efficacy in reducing tumor size and suppressing metastases in models of pancreatic ductal adenocarcinoma. This compound also halts tumor growth in triple-negative and HER2+ breast cancer models, showing potential for reversing drug resistance.